Survival benefit in hepatocellular carcinoma: When an innovative transplant strategy might benefit oncology

The Lancet Oncology

Volumn 12, Issue 7, 2011, Pages 611-612

  Sotiropoulos, Georgios C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR;

CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM;

EID: 79959560835     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70160-7     Document Type: Letter

References (5)

1. Sotiropoulos GC, Drühe N, Sgourakis G, et al. Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?. Dig Dis Sci 2009, 54:2264-2273.
2. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
3. Sotiropoulos GC, Malagó M, Molmenti E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?. Transplantation 2005, 79:483-487.
4. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. Practice Guidelines Committee, American Association for the Study of Liver DiseasesAmerican Association for the Study of Liver Diseases.
5. Vitale A, Morales R Ramirez, Zanus G, et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011, on behalf of the Italian Liver Cancer group, published online June 17. 10.1016/S1470-2045(11)70144-9.